A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host…
Clementia Pharmaceuticals entered the market with a bang, with shares priced above expected price range.
Pharmaceuticals maker Pfizer reported second-quarter earnings before markets opened Tuesday, beating profit estimates by a penny a share, but coming up short on revenues.
No wonder there is a national problem with opioid use. A contributing factor has to be that almost 92 Americans used opioids in 2015.
AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.
Tetraphase Pharmaceuticals saw its shares pull back on Friday after the company announced that it has priced a secondary offering.
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for aggressive investors.
Residents in Pittsburgh were given "misleading" statements by health officials who "deflected" attention from lead-contaminated water, according to a recent report.
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Clementia Pharmaceuticals intends to price more than 7 million shares in a range that will result in an initial public offering valued up to more than $123 million.
Reata Pharmaceuticals saw its shares make an incredible gain to kick off the week after it reported initial data from its mid-stage trial evaluating bardoxolone in patients with chronic kidney disease.
Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) in a close second. However, one…
Shares of Vertex Pharmaceuticals shot up after the company announced dramatic results from its early and mid-stage trials in cystic fibrosis. The stock pushed to an all-time high on the back of these results.
A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the report's top picks: AbbVie, Eli Lilly, Merck, and Shire.
